Search Results | MSF Science Portal

Journal Article

|

Research

Schramm B, Ashakin KA, Firuz W, Hadiuzzaman M, Ben-Farhat J, et al.

2025-04-01 • Lancet Gastroenterology and Hepatology

Journal Article

|

Research

Mazzilli S, Aslam MK, Akhtar J, Miazek M, Wailly Y, et al.

2024-09-27 • BMC Infectious Diseases

BACKGROUND

Hepatitis C virus (HCV) antibody self-testing (HCVST) may help expand screening access and support HCV elimination efforts. Despite potential benefit...

Conference Material

|

Video

Schramm B

2024-07-01 • Epicentre Scientific Day 2024

Conference Material

|

Poster

Ashakin KA, Hadiuzzaman M, Firuz W, Rahman A, Ben-Farhat J, et al.

2024-05-23 • Epicentre Scientific Day 2024

Conference Material

|

Abstract

Schramm B, Hossain FN

2024-05-23 • Epicentre Scientific Day 2024

BACKGROUND

Hepatitis C virus (HCV) is a major cause of liver diseases globally. Transmission is primarily bloodborne through unsafe injections or healthcare practices. Effective...

Conference Material

|

Poster

Firuz W, Ashakin KA, Schramm B, Camelique O, Duka M, et al.

2024-05-16 • MSF Scientific Day International 2024

Journal Article

|

Research

Alam R, Aslam K, Ahmed M, Isaakidis P

2023-09-20 • PLOS Global Public Health

The burden of hepatitis C virus (HCV) infection in Pakistan is amongst the highest in the world. People living in slums are likely to be at high risk of infection. Here, we describe the ...

Journal Article

|

Research

O’Keefe D, Samley K, Bunreth V, Marquardt T, Bobi SE, et al.

2023-04-01 • Bulletin of the World Health Organization

OBJECTIVE
To determine whether a nurse-led model of care for patients with hepatitis C virus (HCV) infections can provide safe and effective diagnosis and treatment in a resource-poo...

Journal Article

|

Research

Loarec A, Gutierrez AG, Muvale G, Couto AM, Nguyen AP, et al.

2023-03-30 • Health Science Reports

BACKGROUND AND AIMS
Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médeci...

Journal Article

|

Research

Saayman E, Hechter V, Kayuni N, Sonderup MW

2023-03-04 • Harm Reduction Journal

BACKGROUND

Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PW...

Journal Article

|

Research

Swe TM, Johnson DC, Mar HT, Thit P, Homan T, et al.

2023-02-17 • Health Science Reports

BACKGROUND AND AIMS
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplificati...

Journal Article

|

Research

Zhang M, O'Keefe D, Iwamoto M, Sann K, Kien A, et al.

2020-05-02 • Journal of Viral Hepatitis

Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF+DCV) facilitate simplified models of care for hepatitis C virus (HCV). ...

Journal Article

|

Research

Kosack CS, Nick S

2016-03-06 • Tropical Medicine and International Health

OBJECTIVE
To evaluate the diagnostic accuracy of the OraQuick HCV rapid antibody test from OraSure and the Multisure HCV antibody assay from MP Biomedicals.

METHODS
Five...

Journal Article

|

Research

Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L, et al.

2020-11-04 • Journal of Viral Hepatitis

Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...

Journal Article

|

Research

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H, et al.

2022-06-21 • Public Health Action

BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...

Journal Article

|

Research

Walker JG, Mafirakureva N, Iwamoto M, Campbell L, Kim CS, et al.

2020-05-31 • Liver International

BACKGROUND & AIMS
In 2016, Médecins Sans Frontières established the first general population Hepatitis C virus (HCV) screening and treatment site in Cambodia, offering free direct-ac...

Journal Article

|

Research

Nouhin J, Iwamoto M, Prak S, Doussett JP, Phon K, et al.

2019-05-13 • Scientific Reports

In Cambodia, little epidemiological data of hepatitis C virus (HCV) is available. All previous studies were limited to only small or specific populations. In the present study, we perfor...

Journal Article

|

Research

Yambasu EE, Reid AJ, Owiti P, Manzi M, Sia Murray MJ, et al.

2017-12-31 • Pan African Medical Journal

INTRODUCTION
Transmissible blood-borne infections are a serious threat to blood transfusion safety in West African countries; and yet blood remains a key therapeutic product in the c...

Journal Article

|

Research

Kosack CS, Nick S, Shanks L

2014-04-13 • Journal of Virological Methods

2% of the world's population lives with a hepatitis C virus (HCV) infection with highest rates in developing countries. The most common mode of transmission takes place via unsafe blood ...

Conference Material

|

Abstract

Sun C

2019-06-13 • Epicentre Scientific Day 2019

This study of HCV prevalence in adults in Cambodia shows higher seropositivity with older age, poverty, lower education levels, and past routine medical interventions.

BACKGROUN...

Science Portal

Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study

Usability and acceptability of self-testing for hepatitis C virus exposure in a high-prevalence urban informal settlement in Karachi, Pakistan

A concern for large-scale treatment access: High prevalence of active HCV infection among forcibly displaced Myanmar nationals residing in camps, Cox’s Bazar, Bangladesh

Prevalence of active hepatitis C virus (HCV) infection and associated factors among forcibly displaced Myanmar nationals residing in camps, Cox’s Bazar, Bangladesh

A concern for large-scale treatment access: High prevalence of active HCV infection among forcibly displaced Myanmar Nationals residing in camps, Cox’s Bazar, Bangladesh

Evaluation of a simplified model of care for chronic hepatitis C infection in Rohingya population in Ukhiya, Cox’s Bazar, Bangladesh

Prevalence and risk factors for hepatitis C virus infection in an informal settlement in Karachi, Pakistan

Nurse-led initiation of hepatitis C care in rural Cambodia

Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5-year retrospective analysis of routine programmatic data

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa

Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study

High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia

Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resource-constrained settings

Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan

Integrating hepatitis C treatment into multidrug-resistant TB care

Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia

Molecular epidemiology of hepatitis C virus in Cambodia during 2016–2017

Hidden dangers-prevalence of blood borne pathogens, hepatitis B, C, HIV and syphilis, among blood donors in Sierra Leone in 2016: opportunities for improvement: a retrospective, cross-sectional study

Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies

Hepatitis C prevalence and risk factors survey in three rural districts